Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Odiparcil · 1 trial · 4 indications
Participants were assessed for VTE at all study visits and at the end of study (Day 10±2) or at early withdrawal. Any participant who remained asymptomatic for VTE at the end of the study did not receive a mandatory bilateral venogram following at least 8 days on study medication. Participants who were withdrawn early and had been objectively confirmed to have a VTE event by a method other than venography were not required to undergo venography. A participant was included in the Independent Central Adjudication Committee (ICAC)-adjudicated incidence of total VTE if he/ she experienced any of adjudicated asymptomatic deep vein thrombosis (DVT) at early withdrawal or after 8-12 days of study treatment and no later than 1 day after end of study treatment, adjudicated symptomatic DVT or pulmonary embolism (PE) at any time during study treatment or death adjudicated to be related to VTE during study treatment.
| Name | Type | Description |
|---|---|---|
| Odiparcil | DRUG | - |
| Warfarin | DRUG | - |
| Coumadin | DRUG | - |
Inclusion Criteria: * Women must be unable to have children. * Will have a total knee replacement. Exclusion Criteria: * Allergic to any X-ray dye. * Allergies or reactions to warfarin or coumadin. * Previous VTE (venous thromboembolism) or deep vein thrombosis (DVT). * On anticoagulation therapy...
Odiparcil is an investigational small molecule being studied for the prevention of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. It is also being evaluated in patients with atrial fibrillation. The drug is in Phase 2 clinical development and is not approved for any use.
Odiparcil is being developed by GSK plc, a global biopharmaceutical company traded on the New York Stock Exchange under the ticker GSK. The company is conducting clinical research to evaluate the drug's safety and efficacy in preventing venous thromboembolism.
Odiparcil is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to assess its potential in preventing venous thromboembolism.
Odiparcil has one completed Phase 2 clinical trial registered as NCT00244725, titled 'Odiparcil For The Prevention Of Venous Thromboembolism.' The trial enrolled 961 participants across multiple countries, including the United States, Australia, Brazil, Canada, India, Israel, and the United Kingdom.
No alternative names for Odiparcil have been reported. The drug is identified by its single name, Odiparcil, in clinical trial registries and research documentation.